Ivonescimab + chemo beats tislelizumab + chemo in Phase III squamous NSCLC trial (HARMONi-6)

Summit Therapeutics Inc.

Primary endpoint PFS met: statistically significant and clinically meaningful improvement by BICR versus tislelizumab combo.
PFS benefit observed in both PD-L1 positive and PD-L1 negative tumors.
No new safety signals identified; full data set to be presented at upcoming medical conference.
Second ivonescimab Phase III to show superiority over PD-(L)1 therapy (after HARMONi-2 in PD-L1+ monotherapy).
Summit enrolling HARMONi-3 global Phase III vs pembrolizumab combo in 1L metastatic NSCLC with registrational intent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.